NASDAQ:COAG Hemab Therapeutics Q1 2026 Earnings Report $25.55 -1.45 (-5.37%) As of 04:00 PM Eastern ProfileEarnings HistoryForecast Hemab Therapeutics EPS ResultsActual EPS-$23.98Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AHemab Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AHemab Therapeutics Announcement DetailsQuarterQ1 2026Date5/21/2026TimeBefore Market OpensConference Call DateThursday, May 21, 2026Conference Call Time7:00AM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Hemab Therapeutics Earnings HeadlinesAnalysts Set Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) Price Target at $41.75June 3, 2026 | americanbankingnews.comHemab Therapeutics Holdings, Inc.'s Quiet Period Will Expire on June 10th (NASDAQ:COAG)June 3, 2026 | americanbankingnews.comHow to get into the SpaceX IPO before June 12Former tech executive and angel investor Jeff Brown - who identified Bitcoin, Tesla, and Nvidia before their historic runs - says the SpaceX IPO is set for June 12 and could be the most anticipated market debut ever. Brown is showing investors how to legally claim a stake before the company goes public, ahead of what chief market strategist Shay Boloor called 'the craziest IPO in the history of the stock market.'June 10 at 1:00 AM | Brownstone Research (Ad)Hemab Therapeutics to Participate in the 2026 Jefferies Global Healthcare ConferenceMay 27, 2026 | globenewswire.comHemab Therapeutics Reports First Quarter 2026 Financial ResultsMay 21, 2026 | markets.businessinsider.comHemab Therapeutics Holdings Inc COAGMay 20, 2026 | morningstar.comMSee More Hemab Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Hemab Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Hemab Therapeutics and other key companies, straight to your email. Email Address About Hemab TherapeuticsHemab Therapeutics (NASDAQ:COAG) is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options. Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders. The company’s work combines biology and translational research to advance potential therapies from discovery through clinical development. Based on publicly available information, Hemab Therapeutics is headquartered in the United States and operates as part of the broader global biopharmaceutical industry. The company’s leadership includes a management team with experience in drug development and hematology-focused research.View Hemab Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Chewy’s Growth Engine Is Stronger Than the Market ThinksEverpure: AI Storage Uncertainty Overshadows Breakneck GrowthIntel Is the Market's Most Mispriced AI HedgeUranium Energy Corp Melts Down—Nuclear Opportunity at HandShort Sellers Are Piling Into Wingstop, But Analysts See Big UpsideOptical Cable Corporation: Strong Earnings, But Hurdles RemainThe J.M. Smucker Company’s Dividend: Too Sweet to Ignore? Upcoming Earnings Adobe (6/11/2026)Accenture (6/18/2026)FedEx (6/23/2026)Micron Technology (6/24/2026)NIKE (6/30/2026)PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
